Clinical trial NCT03184766: Ibuprofen and Pseudoephedrine Comparative Pharmacokinetic Study
Official title: An Open-label, Randomised, Three-way Cross-over, Single Dose, Single Centre, Comparative Pharmacokinetic Study Between Ibuprofen and Pseudoephedrine Liquid Capsules (2x 200 mg Ibuprofen & 30 mg Pseudoephedrine) (Test), Ibuprofen and Pseudoephedrine Tablets (2x 200 mg Ibuprofen & 30 mg Pseudoephedrine) (Comparator 1), and Ibuprofen Liquid Capsules (2x 200 mg Solubilised Ibuprofen) (Comparator 2)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Reckitt Benckiser Healthcare (UK) Limited
Sponsor class: INDUSTRY
Collaborators: name: Simbec Research
First posted: 2017-06-14
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This comparative pharmacokinetic study is being conducted to provide supporting evidence for inclusion in dossiers to regulatory authorities for an Article 8(3) of Directive 2001/83/EC abridged application for ibuprofen and pseudoephedrine liquid capsules (200 mg ibuprofen \& 30 mg pseudoephedrine).


Eligibility criteria: Inclusion Criteria:

1. Male or female subjects who have given written informed consent.
2. Age: ≥ 18 years ≤ 50 years.
3. Body Mass Index (BMI) of ≥ 20 and ≤ 30 kg/m2.
4. Healthy as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
5. Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception unless of non-childbearing potential or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject from first dose until 3 months after the final dose of study medication.
6. Female subject of non-child bearing potential with negative pregnancy test at the screening visit.
7. Male subject willing to use an effective method of contraception unless anatomically sterile or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject from first dose until 3 months after the final dose of study medication.

Exclusion Criteria:

1. Pregnant or lactating females.
2. A history and/or presence of significant disease of any body system, including psychiatric disorders.
3. Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.
4. A history of allergy or intolerance related to treatment with ibuprofen, aspirin, other NSAIDs, pseudoephedrine, other sympathomimetic or catecholamine derivative decongestant drugs or the excipients of the formulations.
5. A history of or active peptic or duodenal ulcers or gastro-intestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.
6. A history of hypertension or hypertension that is currently treated with antihypertensive medication.
7. A history of frequent dyspepsia, e.g. heartburn or indigestion.
8. A history of migraine.
9. Current smokers and ex-smokers who have smoked or used nicotine replacement products during the previous 6 months prior to first dosing.
10. A history of substance abuse (including alcohol).
11. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc.; total caffeine intake per day above 300 mg).
12. Those with positive screen/test for drugs of abuse and alcohol.
13. Those with a positive screen for ibuprofen.
14. Ingestion of a prescribed drug at any time in the 14 days before the first dose of study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers 30 days prior to the first dose of study medication.
15. Ingestion of an over-the-counter preparation within 7 days before the first dose of study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen, other NSAIDs or decongestants.
16. Donation of blood in quantity \> 400 ml e.g. to the blood transfusion service in the 12 weeks prior to the first dose of study medication
17. Known human immune deficiency virus (HIV) positive status, or a positive viral serology screen.
18. Topical use of ibuprofen within 7 days before the first dose of study medication.
19. Those previously randomised into this study.
20. Those who are an employee at the study site.
21. Those who are a partner or first degree relative of the Investigator.
22. Those who have participated in a clinical trial in the 12 weeks prior to the first dose of study medication.
23. Those unable in the opinion of the Investigator to comply fully with the study requirements.
24. Those who have consumed grapefruit or grapefruit juice, pummelo or Seville oranges in the 7 days prior to randomisation.
25. Those who are unwilling to consume gelatine of animal origin.

Primary outcomes:
measure: Pseudoephedrine AUC0-t for Test vs. Comparator 1.
timeFrame: PK Analysis: 0-48hrs
measure: Pseudoephedrine Cmax for Test vs. Comparator 1.
timeFrame: PK Analysis: 0-48hrs
measure: Ibuprofen AUC0-t for Test vs. Comparator 2.
timeFrame: PK Analysis: 0-48hrs
measure: Ibuprofen Cmax for Test vs. Comparator 2.
timeFrame: PK Analysis: 0-48hrs
Secondary outcomes:
measure: Ibuprofen AUC0-t for Test vs. Comparator 1.
timeFrame: PK Analysis: 0-48hrs
measure: Ibuprofen Cmax for Test vs. Comparator 1.
timeFrame: PK Analysis: 0-48hrs
measure: Assessment of how fast the ibuprofen from the Test product starts to be absorbed and how quickly it reaches the therapeutic level.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
measure: Pharmacokinetic parameters will be assessed as secondary endpoints.
timeFrame: PK Analysis: 0-48hrs
Other outcomes:
measure: The occurrence of Adverse Events.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
measure: Change from baseline in oral temperature.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
measure: Change from baseline in resting heart rate.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
measure: Change from baseline in resting blood pressure.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
measure: Change from baseline in haematology testing.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
measure: Change from baseline in biochemistry testing.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
measure: Change from baseline in urinary testing.
timeFrame: Through study completion - Screening to study follow-up (Approx 8 weeks)
Locations:
Study officials:
affiliation: Simbec Research
name: Robert Adams, MBBS
role: PRINCIPAL_INVESTIGATOR
References: